{"gene":"NR0B2","run_date":"2026-04-29T11:37:57","timeline":{"discoveries":[{"year":2004,"finding":"Bile acid activation of FXR induces SHP (NR0B2) expression, and SHP is required for FXR-mediated repression of SREBP-1c and its lipogenic target genes, thereby lowering triglyceride levels. Genetic epistasis using SHP-null and LXRα/β-null mice demonstrated that both SHP and LXRα/β are essential for this repressive pathway.","method":"Mouse knockout models (SHP-/-, LXRα/β-/-), molecular and cellular assays, animal models of hypertriglyceridemia","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with multiple knockout lines, replicated across molecular and animal models","pmids":["15146238"],"is_preprint":false},{"year":2004,"finding":"SHP (NR0B2) is expressed in hepatic stellate cells (HSCs) and, downstream of FXR activation, directly binds JunD and inhibits AP-1 DNA binding induced by thrombin, thereby protecting against liver fibrosis. This was demonstrated using SHP-overexpressing and SHP-deficient HSC-T6 cell lines.","method":"Retroviral overexpression and siRNA knockdown of SHP in HSC-T6 cells; protein binding assays; in vivo rodent fibrosis models","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function and gain-of-function with defined molecular mechanism (JunD binding, AP-1 inhibition), supported by in vivo models","pmids":["15521018"],"is_preprint":false},{"year":2005,"finding":"Crystal structure of the hLRH-1 ligand-binding domain in complex with the NR box 1 motif of human SHP (NR0B2) at 1.9 Å resolution revealed that SHP contacts the AF-2 region of hLRH-1 using selective structural motifs, establishing the structural basis for SHP-mediated corepression of LRH-1.","method":"X-ray crystallography (1.9 Å), mass spectrometry, in vivo reporter assays with LBD pocket mutations","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional validation by mutagenesis and in vivo assays","pmids":["15723037"],"is_preprint":false},{"year":2002,"finding":"SHP (NR0B2) interacts with and potently inhibits glucocorticoid receptor (GR) transcriptional activity via a functional second NR-box within SHP. SHP antagonizes the GR coactivator PGC-1 and represses the PEPCK promoter. Co-expression of GFP-tagged GR with SHP caused intranuclear redistribution of GR, an effect requiring SHP's inhibitory function.","method":"Mammalian and yeast two-hybrid, transient cotransfection assays, GFP imaging, inhibition-deficient SHP mutants","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (protein interaction, reporter assays, live imaging, mutagenesis) in a single study","pmids":["12324453"],"is_preprint":false},{"year":1998,"finding":"SHP (NR0B2) interacts with estrogen receptor alpha (ERα) in an agonist-dependent manner via its NR-box motifs (the same domain used to interact with RXR and TR), and inhibits estradiol-dependent ERα transcriptional activation ~5-fold. SHP also interacts with ERβ in a ligand-independent manner.","method":"Mammalian and yeast two-hybrid, GST pull-down, deletion mutant mapping, transient cotransfection reporter assays","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal binding assays plus functional reporter assays, multiple ER isoforms tested","pmids":["9773978"],"is_preprint":false},{"year":2001,"finding":"SHP (NR0B2) inhibits androgen receptor (AR) transcriptional activity by up to 97% through ligand-dependent interaction with the AR ligand-binding domain via LXXI/LL motifs, and also interacts with the AR N-terminal domain, enabling inhibition of both LBD- and NTD-dependent transactivation. SHP competes with AR coactivators FHL2 and TIF2.","method":"Two-hybrid assays, deletion mutant analysis, transient cotransfection reporter assays, coactivator competition assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple interaction assays plus functional reporter data with domain mapping and coactivator competition","pmids":["11735420"],"is_preprint":false},{"year":2010,"finding":"SHP (NR0B2) recruits SIRT1 histone deacetylase to inhibit LRH-1 transactivation in an NR-specific manner. SHP and SIRT1 co-immunoprecipitate and co-localize in vivo. SIRT1 deacetylates histones H3 and H4 at LRH-1 target gene promoters (CYP7A1, SHP itself), and inhibition of SIRT1 reverses SHP-mediated repression of bile acid synthesis.","method":"Co-IP, co-localization, ChIP assays, dominant-negative SIRT1, siRNA knockdown, luciferase reporter assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, ChIP, and functional assays with multiple loss-of-function approaches","pmids":["20375098"],"is_preprint":false},{"year":2013,"finding":"Crystal structure of SHP (NR0B2) in complex with EID1 revealed that EID1 binds an unexpected N-terminal site on SHP (mimicking helix H1 of the NR LBD), distinct from the classical C-terminal H12 cofactor-binding site. Mutations at this interface diminish SHP-EID1 interactions and impair SHP repressor activity.","method":"X-ray crystallography, mutagenesis, protein interaction assays, functional reporter assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutagenesis validation and functional assays","pmids":["24379397"],"is_preprint":false},{"year":2020,"finding":"FGF15/19 activates SHP (NR0B2) via phosphorylation, and phosphorylated SHP recruits DNMT3A to lipogenic gene promoters, leading to epigenetic repression via DNA methylation. This FGF15/19-SHP-DNMT3A axis physiologically represses hepatic lipogenesis in the late fed state.","method":"Comparative genomics, adenoviral overexpression, SHP knockout mice, ChIP, bisulfite sequencing, phosphorylation assays, DNMT3A-knockout validation","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods including phosphorylation, ChIP, DNA methylation, and in vivo knockout models","pmids":["33235221"],"is_preprint":false},{"year":2010,"finding":"FXR activates SHP (NR0B2) transcription through two FXR response elements (FXRREs): one in the proximal promoter and one in a novel downstream 3'-enhancer of the Nr0b2 gene. These two FXRREs interact to form a head-to-tail chromatin loop as detected by chromatin conformation capture assay, enhancing transcription efficiency.","method":"ChIP-seq, ChIP-qPCR, chromatin conformation capture (3C), luciferase reporter assays, site-directed mutagenesis","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 1–2 — 3C chromatin looping plus ChIP-seq and mutagenesis provide strong mechanistic evidence","pmids":["20444884"],"is_preprint":false},{"year":2010,"finding":"Combined deletion of both Fxr and Shp (NR0B2) in mice causes juvenile-onset cholestasis more severe than either single knockout, demonstrating that FXR and SHP have partially non-overlapping functions. The double knockout induced Cyp17a1, elevated 17-hydroxyprogesterone (17-OHP), and 17-OHP treatment alone was sufficient to reproduce liver injury.","method":"Double knockout mouse model, gene expression analysis, serum metabolite measurement, pharmacological 17-OHP treatment","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with double KO and pharmacological rescue, replicated across multiple endpoints","pmids":["21123943"],"is_preprint":false},{"year":2002,"finding":"SHP (NR0B2) inhibits CYP7A1 transcription by associating with LRH-1 (liver receptor homolog-1), an obligate transcriptional activator of CYP7A1, thereby repressing bile acid synthesis downstream of FXR-induced SHP expression.","method":"Molecular and cellular studies reviewed; interaction assays and transcriptional reporter assays cited across multiple studies","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 3 — review summarizing interaction data; primary experiments cited from other labs","pmids":["11907135"],"is_preprint":false},{"year":2009,"finding":"SHP (NR0B2) activates miR-206 expression through a cascade dual inhibitory mechanism: SHP inhibits ERRγ, which reduces YY1 expression, which in turn de-represses AP-1 activity on the miR-206 promoter. ChIP confirmed ERRγ binding to the YY1 promoter and AP1/YY1 binding to the miR-206 promoter.","method":"Microarray profiling, RACE, ChIP assays, siRNA knockdown, promoter reporter assays, forced expression","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (ChIP, siRNA, reporter assays) establishing a cascade mechanism","pmids":["19721712"],"is_preprint":false},{"year":2010,"finding":"SHP (NR0B2) polymorphisms R38H and K170N impair nuclear translocation. K170N increases susceptibility to ubiquitination-mediated degradation and blocks SHP acetylation, leading to loss of repressive activity on ERRγ and HNF4α (but not LRH-1). K170N also impairs recruitment of SHP, HNF4α, HDAC1, and HDAC3 to the apoCIII promoter.","method":"SNP identification, nuclear localization assays, ubiquitination assays, acetylation assays, ChIP, reporter assays, molecular dynamics simulation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple biochemical assays plus structural modeling, mutagenesis, and ChIP","pmids":["20516075"],"is_preprint":false},{"year":2011,"finding":"SHP (NR0B2) represses Dnmt1 expression by inhibiting ERRγ transactivation at ERRγ response elements in the Dnmt1 promoter, reducing ERRγ recruitment and shifting local chromatin to an inactive conformation.","method":"Luciferase reporter assays, ChIP assays, ERRγ and SHP overexpression/knockdown","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and reporter assays from a single lab","pmids":["21459093"],"is_preprint":false},{"year":2010,"finding":"SHP (NR0B2) overexpression in adipose tissue increases body weight and adiposity in young transgenic mice, impairs adaptive thermogenesis on high-fat diet, and decreases energy expenditure and physical activity, establishing a direct role for adipose SHP in metabolic regulation.","method":"Fat-specific SHP transgenic mice, metabolic rate measurement, cold-exposure studies, high-fat diet feeding, brown fat ultrastructural analysis","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — tissue-specific transgenic model with defined metabolic phenotypes, single lab","pmids":["20124506"],"is_preprint":false},{"year":2010,"finding":"SHP (NR0B2) physically interacts with Runx2 on the osteocalcin gene promoter and increases Runx2 transactivity by competing with HDAC4, which normally inhibits Runx2 DNA binding. SHP-/- mice show decreased bone mass and reduced osteoblast numbers.","method":"Co-IP, ChIP, reporter assays, SHP-/- mice, adenoviral overexpression/knockdown, ectopic bone formation assay","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (Co-IP, ChIP, KO mice, functional assays) with defined molecular mechanism","pmids":["19594294"],"is_preprint":false},{"year":2015,"finding":"SHP (NR0B2) inhibits transcriptional activation of Bhmt and cystathionine γ-lyase by FOXA1, thereby controlling oscillatory homocysteine homeostasis. SHP-null mice show altered timing of expression of homocysteine metabolism genes and resistance to ethanol/homocysteine-induced hyperhomocysteinemia and glucose intolerance.","method":"SHP-null and BHMT-null mouse models, RNA-seq, ChIP assays, metabolomics","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — KO mouse model combined with ChIP and metabolomics establishing FOXA1-SHP interaction and gene targets","pmids":["25701738"],"is_preprint":false},{"year":2018,"finding":"AhR and SHP (NR0B2) regulate phosphatidylcholine and S-adenosylmethionine levels by controlling Pemt and Gnmt expression. Insulin/PKB signaling translocates AhR to the nucleus to induce these genes in the early fed state, while FGF15 signaling-activated SHP blocks this induction in the late fed state.","method":"SHP-null and FGF15-null mice, adenoviral expression, ChIP assays, metabolomics","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — genetic KO models combined with ChIP and metabolomics establishing AhR-SHP epistasis","pmids":["29416063"],"is_preprint":false},{"year":2016,"finding":"A small molecule (DSHN) activates SHP (NR0B2) by transcriptionally upregulating Shp mRNA and stabilizing SHP protein by preventing ubiquitination and degradation. Activated SHP represses Ccl2 expression by inhibiting p65-mediated CCL2 promoter activity, thereby inhibiting HCC cell migration.","method":"Small molecule microarray binding assay, RNA-seq, luciferase reporter assays, SHP overexpression/knockdown, ubiquitination assay, Shp-/- mice","journal":"Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods with in vivo validation in Shp-/- mice","pmids":["27486225"],"is_preprint":false},{"year":2014,"finding":"SHP (NR0B2) is recruited by NF-κB p65 and forms a SHP/NF-κB p65 complex that binds the PDCD5 gene promoter, activating PDCD5 expression and triggering apoptosis via increased Bax and cytochrome C release in breast cancer cells.","method":"ChIP-on-chip, ChIP assay, luciferase reporter assay, knockdown/overexpression of SHP and PDCD5, apoptosis assays","journal":"Apoptosis","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and functional assays, single lab","pmids":["24343129"],"is_preprint":false},{"year":2004,"finding":"A novel missense variant G93D in NR0B2 (SHP) shows reduced in vitro inhibition of HNF-4α transactivation of the HNF-1α promoter in MIN6-m9 and HepG2 cells, establishing that Gly-93 is functionally important for SHP's corepressor activity.","method":"SSCP/heteroduplex mutation screening, transfection reporter assays in MIN6-m9 and HepG2 cells","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro functional assay with human variant, single lab","pmids":["15459958"],"is_preprint":false},{"year":2018,"finding":"ChREBP, rather than SHP (NR0B2), is the primary regulator of hepatic MTTP expression and VLDL secretion under normal conditions. Shp-/- mice show similar Mttp mRNA, protein, and VLDL secretion to wild-type, while Chrebp-/-Shp-/- and Chrebp-/- mice show markedly lower levels, demonstrating genetic epistasis.","method":"Shp-/- and Chrebp-/- single and double knockout mice, adenoviral overexpression in primary hepatocytes, VLDL secretion assays, promoter reporter assays","journal":"Nutrients","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis with double KO, single lab","pmids":["29518948"],"is_preprint":false}],"current_model":"NR0B2/SHP is an atypical nuclear receptor lacking a DNA-binding domain that acts as a broadly inducible transcriptional corepressor: it is transcriptionally induced by FXR (via chromatin looping between a proximal FXRRE and a distal 3' enhancer in the Nr0b2 gene), and FGF15/19-mediated phosphorylation of SHP enables it to recruit epigenetic repressors including SIRT1 histone deacetylase and DNMT3A to lipogenic and other metabolic gene promoters; SHP directly interacts with numerous nuclear receptors (LRH-1, GR, ERα, AR, ERRγ, HNF-4α, Runx2) and transcription factors (JunD/AP-1, FOXA1, p65) via its NR-box motifs, inhibiting their transcriptional activity through competition with coactivators and recruitment of corepressor complexes, and its stability is regulated by ubiquitination and acetylation at Lys-170."},"narrative":{"teleology":[{"year":1998,"claim":"Establishing that SHP functions as a ligand-modulated inhibitor of steroid receptors answered the question of how an orphan NR lacking a DBD exerts transcriptional effects — SHP directly binds ERα via NR-box motifs and represses estrogen-dependent transactivation.","evidence":"Mammalian/yeast two-hybrid, GST pull-down, and reporter assays mapping NR-box-dependent SHP–ERα interaction","pmids":["9773978"],"confidence":"High","gaps":["Endogenous ligand for SHP's LBD pocket not identified","In vivo relevance of SHP–ERα interaction not tested"]},{"year":2001,"claim":"Demonstrating that SHP inhibits AR through both LBD- and NTD-dependent interactions and competes with coactivators FHL2/TIF2 broadened the corepressor model beyond steroid receptor LBD contacts.","evidence":"Two-hybrid, deletion mapping, reporter assays, and coactivator competition assays","pmids":["11735420"],"confidence":"High","gaps":["Physiological context of SHP–AR antagonism undefined","No in vivo data"]},{"year":2002,"claim":"Showing that SHP antagonizes GR by competing with PGC-1 and causing intranuclear redistribution of GR connected SHP to gluconeogenic gene regulation (PEPCK).","evidence":"Mammalian/yeast two-hybrid, GFP live imaging, reporter assays with inhibition-deficient SHP mutants","pmids":["12324453"],"confidence":"High","gaps":["In vivo metabolic consequence of SHP–GR antagonism not demonstrated"]},{"year":2004,"claim":"Genetic epistasis with SHP-null and LXRα/β-null mice established that FXR-induced SHP is required for repression of SREBP-1c and triglyceride lowering, positioning SHP as an essential node in the bile acid–lipogenesis regulatory axis.","evidence":"SHP−/− and LXRα/β−/− knockout mice, molecular assays, hypertriglyceridemia models","pmids":["15146238"],"confidence":"High","gaps":["Mechanism by which SHP inhibits LXRα-mediated SREBP-1c transcription not fully resolved at the chromatin level"]},{"year":2004,"claim":"Identification of SHP–JunD binding and inhibition of AP-1 activity in hepatic stellate cells extended SHP's repressor role beyond nuclear receptors to non-NR transcription factors and linked it to protection against liver fibrosis.","evidence":"Retroviral overexpression and siRNA knockdown in HSC-T6 cells, protein binding assays, rodent fibrosis models","pmids":["15521018"],"confidence":"High","gaps":["Direct structural basis of SHP–JunD interaction unknown"]},{"year":2005,"claim":"The 1.9 Å crystal structure of SHP NR-box 1 bound to the LRH-1 AF-2 surface provided the first atomic-level explanation for how SHP mimics coactivator binding to repress target NRs.","evidence":"X-ray crystallography, mass spectrometry, mutagenesis, in vivo reporter assays","pmids":["15723037"],"confidence":"High","gaps":["Structure of full-length SHP or its complex with other NR partners not determined"]},{"year":2009,"claim":"Discovery that SHP activates miR-206 through a cascade (SHP→ERRγ→YY1→AP-1) revealed SHP can upregulate gene expression indirectly through serial repression.","evidence":"Microarray, ChIP, siRNA knockdown, reporter assays","pmids":["19721712"],"confidence":"High","gaps":["Physiological significance of miR-206 regulation by SHP not validated in vivo"]},{"year":2010,"claim":"Multiple 2010 studies resolved how SHP's own transcription is controlled (FXR-mediated chromatin looping), how SHP represses chromatin (SIRT1 recruitment to deacetylate H3/H4), and how post-translational modifications (ubiquitination, acetylation at K170) regulate SHP stability and partner selectivity.","evidence":"ChIP-seq, 3C chromatin conformation capture, Co-IP/co-localization, ubiquitination/acetylation assays, SHP−/− mice, molecular dynamics, SNP functional analysis","pmids":["20444884","20375098","20516075"],"confidence":"High","gaps":["Kinase responsible for SHP phosphorylation not yet assigned in this context","Whether K170 acetylation is enzymatically reversible in vivo unknown"]},{"year":2010,"claim":"SHP−/− mice exhibit decreased bone mass and reduced osteoblast numbers; SHP promotes Runx2 transactivation by displacing HDAC4 from the osteocalcin promoter, establishing a coactivator-like role for SHP in bone.","evidence":"Co-IP, ChIP, reporter assays, SHP−/− mice, ectopic bone formation assay","pmids":["19594294"],"confidence":"High","gaps":["Upstream signals activating SHP in osteoblasts unidentified","Whether SHP–Runx2 interaction is NR-box-dependent not shown"]},{"year":2011,"claim":"Double knockout of Fxr and Shp caused juvenile cholestasis more severe than either single KO, with ectopic Cyp17a1 induction and elevated 17-OHP, revealing non-overlapping protective functions of FXR and SHP.","evidence":"Fxr−/−;Shp−/− double KO mice, gene expression, serum metabolites, pharmacological 17-OHP challenge","pmids":["21123943"],"confidence":"High","gaps":["Mechanism by which SHP represses Cyp17a1 not determined"]},{"year":2013,"claim":"The SHP–EID1 crystal structure revealed a non-canonical cofactor-binding site at the N-terminal helix H1 of SHP's LBD, distinct from the classical AF-2 groove, expanding the structural repertoire of SHP-mediated repression.","evidence":"X-ray crystallography, mutagenesis, protein interaction and reporter assays","pmids":["24379397"],"confidence":"High","gaps":["Whether the H1 site operates simultaneously with the AF-2 site in a ternary complex is unknown"]},{"year":2015,"claim":"SHP was shown to govern oscillatory homocysteine homeostasis by inhibiting FOXA1 transactivation of Bhmt and Cth, connecting SHP to one-carbon metabolism and linking its loss to ethanol-induced hyperhomocysteinemia.","evidence":"SHP-null and BHMT-null mice, RNA-seq, ChIP, metabolomics","pmids":["25701738"],"confidence":"High","gaps":["Whether circadian regulation of SHP drives the oscillatory pattern not tested"]},{"year":2018,"claim":"SHP was placed into a temporal feeding-cycle circuit: insulin/PKB-driven AhR activates Pemt/Gnmt in the early fed state, while FGF15-activated SHP blocks this induction in the late fed state, controlling phosphatidylcholine and SAM levels.","evidence":"SHP-null and FGF15-null mice, ChIP, metabolomics","pmids":["29416063"],"confidence":"High","gaps":["Direct SHP–AhR physical interaction not demonstrated"]},{"year":2020,"claim":"The FGF15/19–SHP–DNMT3A epigenetic axis was defined: FGF15/19-mediated phosphorylation of SHP enables DNMT3A recruitment to lipogenic promoters, causing DNA methylation-dependent repression in the late fed state.","evidence":"Comparative genomics, SHP-KO mice, ChIP, bisulfite sequencing, phosphorylation assays, DNMT3A-KO validation","pmids":["33235221"],"confidence":"High","gaps":["Specific phosphorylation site(s) on SHP mediating DNMT3A recruitment not mapped","Reversibility and dynamics of DNA methylation marks unclear"]},{"year":null,"claim":"Key unresolved questions include the identity of any endogenous SHP ligand, the full-length SHP structure, how SHP switches between corepressor and apparent coactivator roles (e.g., Runx2), and the tissue-specific regulation of SHP post-translational modifications.","evidence":"","pmids":[],"confidence":"Low","gaps":["No endogenous ligand identified","No full-length SHP structure","Mechanism governing context-dependent coactivator vs corepressor activity unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,3,4,5,6,12,14,17]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,6,8,16,19,20]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,6,13]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,6,8,9,12,14,17,19,20]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,8,15,17,18]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,18]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[6,8]}],"complexes":[],"partners":["NR5A2","NR1H4","NR3C1","ESR1","AR","ESRRG","SIRT1","DNMT3A"],"other_free_text":[]},"mechanistic_narrative":"NR0B2 (SHP) is an atypical orphan nuclear receptor that lacks a DNA-binding domain and functions as a versatile transcriptional corepressor in hepatic bile acid, lipid, and one-carbon metabolism, as well as in bone remodeling and inflammatory signaling. SHP is transcriptionally induced by FXR through chromatin looping between proximal and distal FXR response elements, and is post-translationally activated by FGF15/19-mediated phosphorylation, which enables recruitment of epigenetic silencing machinery including SIRT1 histone deacetylase and DNMT3A DNA methyltransferase to target gene promoters [PMID:20444884, PMID:20375098, PMID:33235221]. SHP binds a broad array of nuclear receptors (LRH-1, GR, ERα, AR, ERRγ, HNF-4α) and transcription factors (JunD/AP-1, FOXA1, p65) through its NR-box motifs, competing with coactivators at the AF-2 surface to repress transcription of genes controlling bile acid synthesis (CYP7A1), lipogenesis (SREBP-1c targets), gluconeogenesis (PEPCK), and homocysteine metabolism (Bhmt, Cth) [PMID:15723037, PMID:15146238, PMID:12324453, PMID:25701738]. SHP protein stability is regulated by ubiquitination and acetylation at Lys-170, and naturally occurring variants such as K170N and R38H impair nuclear translocation and corepressor function [PMID:20516075]."},"prefetch_data":{"uniprot":{"accession":"Q15466","full_name":"Nuclear receptor subfamily 0 group B member 2","aliases":["Orphan nuclear receptor SHP","Small heterodimer partner"],"length_aa":257,"mass_kda":28.1,"function":"Transcriptional regulator that acts as a negative regulator of receptor-dependent signaling pathways (PubMed:22504882). Specifically inhibits transactivation of the nuclear receptor with which it interacts (PubMed:22504882). Inhibits transcriptional activity of NEUROD1 on E-box-containing promoter by interfering with the coactivation function of the p300/CBP-mediated transcription complex for NEUROD1 (PubMed:14752053). Essential component of the liver circadian clock which via its interaction with NR1D1 and RORG regulates NPAS2-mediated hepatic lipid metabolism (By similarity). Regulates the circadian expression of cytochrome P450 (CYP) enzymes (By similarity). Represses: NR5A2 and HNF4A to down-regulate CYP2C38, NFLI3 to up-regulate CYP2A5, BHLHE41/HNF1A axis to up-regulate CYP1A2, CYP2E1 and CYP3A11, and NR1D1 to up-regulate CYP2B10, CYP4A10 and CYP4A14 (By similarity)","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q15466/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NR0B2","classification":"Not Classified","n_dependent_lines":49,"n_total_lines":1208,"dependency_fraction":0.04056291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NR0B2","total_profiled":1310},"omim":[{"mim_id":"611135","title":"KLOTHO, BETA; KLB","url":"https://www.omim.org/entry/611135"},{"mim_id":"604630","title":"NUCLEAR RECEPTOR SUBFAMILY 0, GROUP B, MEMBER 2; NR0B2","url":"https://www.omim.org/entry/604630"},{"mim_id":"604453","title":"NUCLEAR RECEPTOR SUBFAMILY 5, GROUP A, MEMBER 2; NR5A2","url":"https://www.omim.org/entry/604453"},{"mim_id":"603826","title":"NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, MEMBER 4; NR1H4","url":"https://www.omim.org/entry/603826"},{"mim_id":"602397","title":"ATPase, CLASS I, TYPE 8B, MEMBER 1; ATP8B1","url":"https://www.omim.org/entry/602397"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":72.2},{"tissue":"liver","ntpm":140.3}],"url":"https://www.proteinatlas.org/search/NR0B2"},"hgnc":{"alias_symbol":["SHP"],"prev_symbol":[]},"alphafold":{"accession":"Q15466","domains":[{"cath_id":"1.10.565.10","chopping":"40-113_140-256","consensus_level":"medium","plddt":92.4177,"start":40,"end":256}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15466","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15466-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15466-F1-predicted_aligned_error_v6.png","plddt_mean":81.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NR0B2","jax_strain_url":"https://www.jax.org/strain/search?query=NR0B2"},"sequence":{"accession":"Q15466","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15466.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15466/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15466"}},"corpus_meta":[{"pmid":"15146238","id":"PMC_15146238","title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.","date":"2004","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15146238","citation_count":1125,"is_preprint":false},{"pmid":"12826400","id":"PMC_12826400","title":"The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.","date":"2003","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12826400","citation_count":1014,"is_preprint":false},{"pmid":"10364425","id":"PMC_10364425","title":"Suppression of SHP-2 and ERK signalling promotes self-renewal of mouse embryonic stem cells.","date":"1999","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/10364425","citation_count":430,"is_preprint":false},{"pmid":"15521018","id":"PMC_15521018","title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.","date":"2004","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15521018","citation_count":393,"is_preprint":false},{"pmid":"9244303","id":"PMC_9244303","title":"Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling.","date":"1997","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9244303","citation_count":380,"is_preprint":false},{"pmid":"19290938","id":"PMC_19290938","title":"SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19290938","citation_count":299,"is_preprint":false},{"pmid":"11085989","id":"PMC_11085989","title":"Divergent roles of SHP-2 in ERK activation by leptin receptors.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11085989","citation_count":289,"is_preprint":false},{"pmid":"10579910","id":"PMC_10579910","title":"Shp-2 tyrosine phosphatase: signaling one cell or many.","date":"1999","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/10579910","citation_count":245,"is_preprint":false},{"pmid":"12657462","id":"PMC_12657462","title":"The function of the protein tyrosine phosphatase SHP-1 in cancer.","date":"2003","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/12657462","citation_count":237,"is_preprint":false},{"pmid":"17157040","id":"PMC_17157040","title":"SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production.","date":"2006","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/17157040","citation_count":206,"is_preprint":false},{"pmid":"20970497","id":"PMC_20970497","title":"Role of nuclear receptor SHP in metabolism and cancer.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/20970497","citation_count":196,"is_preprint":false},{"pmid":"16354697","id":"PMC_16354697","title":"Focal adhesion kinase is a substrate and downstream effector of SHP-2 complexed with Helicobacter pylori CagA.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16354697","citation_count":174,"is_preprint":false},{"pmid":"15723037","id":"PMC_15723037","title":"Modulation of human nuclear receptor LRH-1 activity by phospholipids and SHP.","date":"2005","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15723037","citation_count":173,"is_preprint":false},{"pmid":"16084691","id":"PMC_16084691","title":"A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail.","date":"2005","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/16084691","citation_count":144,"is_preprint":false},{"pmid":"9261115","id":"PMC_9261115","title":"Src kinase activity is regulated by the SHP-1 protein-tyrosine phosphatase.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9261115","citation_count":141,"is_preprint":false},{"pmid":"32184441","id":"PMC_32184441","title":"Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/32184441","citation_count":140,"is_preprint":false},{"pmid":"11191350","id":"PMC_11191350","title":"The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions.","date":"2000","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/11191350","citation_count":137,"is_preprint":false},{"pmid":"11907135","id":"PMC_11907135","title":"Regulation of cholesterol-7alpha-hydroxylase: BAREly missing a SHP.","date":"2002","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/11907135","citation_count":130,"is_preprint":false},{"pmid":"17442246","id":"PMC_17442246","title":"Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome.","date":"2007","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/17442246","citation_count":126,"is_preprint":false},{"pmid":"10488096","id":"PMC_10488096","title":"SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10488096","citation_count":121,"is_preprint":false},{"pmid":"16275121","id":"PMC_16275121","title":"Transcriptional corepression by SHP: molecular mechanisms and physiological consequences.","date":"2005","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/16275121","citation_count":117,"is_preprint":false},{"pmid":"11114521","id":"PMC_11114521","title":"The protein tyrosine phosphatase Shp-2 regulates RhoA activity.","date":"2000","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/11114521","citation_count":116,"is_preprint":false},{"pmid":"16617349","id":"PMC_16617349","title":"The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis.","date":"2006","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16617349","citation_count":112,"is_preprint":false},{"pmid":"12324453","id":"PMC_12324453","title":"Glucocorticoid signaling is perturbed by the atypical orphan receptor and corepressor SHP.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12324453","citation_count":111,"is_preprint":false},{"pmid":"12421673","id":"PMC_12421673","title":"Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response.","date":"2002","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12421673","citation_count":109,"is_preprint":false},{"pmid":"9773978","id":"PMC_9773978","title":"Inhibition of estrogen receptor action by the orphan receptor SHP (short heterodimer partner).","date":"1998","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/9773978","citation_count":106,"is_preprint":false},{"pmid":"21123943","id":"PMC_21123943","title":"Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis.","date":"2010","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/21123943","citation_count":105,"is_preprint":false},{"pmid":"10594032","id":"PMC_10594032","title":"Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10594032","citation_count":104,"is_preprint":false},{"pmid":"23391724","id":"PMC_23391724","title":"SHP-1 phosphatase activity counteracts increased T cell receptor affinity.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23391724","citation_count":101,"is_preprint":false},{"pmid":"9418864","id":"PMC_9418864","title":"Structural determinants of SHP-2 function and specificity in Xenopus mesoderm induction.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9418864","citation_count":99,"is_preprint":false},{"pmid":"11159516","id":"PMC_11159516","title":"Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11159516","citation_count":97,"is_preprint":false},{"pmid":"10506221","id":"PMC_10506221","title":"Regulation of acidification and apoptosis by SHP-1 and Bcl-2.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10506221","citation_count":95,"is_preprint":false},{"pmid":"15933714","id":"PMC_15933714","title":"Receptor-stimulated oxidation of SHP-2 promotes T-cell adhesion through SLP-76-ADAP.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15933714","citation_count":95,"is_preprint":false},{"pmid":"12615921","id":"PMC_12615921","title":"Identification of Shp-2 as a Stat5A phosphatase.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12615921","citation_count":93,"is_preprint":false},{"pmid":"14676626","id":"PMC_14676626","title":"SHP-2 and myeloid malignancies.","date":"2004","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/14676626","citation_count":93,"is_preprint":false},{"pmid":"9814969","id":"PMC_9814969","title":"Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2.","date":"1998","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9814969","citation_count":92,"is_preprint":false},{"pmid":"9507023","id":"PMC_9507023","title":"Growth hormone regulation of SIRP and SHP-2 tyrosyl phosphorylation and association.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9507023","citation_count":79,"is_preprint":false},{"pmid":"12370245","id":"PMC_12370245","title":"Gab1 and SHP-2 promote Ras/MAPK regulation of epidermal growth and differentiation.","date":"2002","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12370245","citation_count":75,"is_preprint":false},{"pmid":"21393858","id":"PMC_21393858","title":"SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans.","date":"2011","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/21393858","citation_count":75,"is_preprint":false},{"pmid":"36581713","id":"PMC_36581713","title":"SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses.","date":"2022","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36581713","citation_count":71,"is_preprint":false},{"pmid":"29776962","id":"PMC_29776962","title":"SHP-1 Acts as a Tumor Suppressor in Hepatocarcinogenesis and HCC Progression.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29776962","citation_count":71,"is_preprint":false},{"pmid":"11735420","id":"PMC_11735420","title":"Characterization of the interaction between androgen receptor and a new transcriptional inhibitor, SHP.","date":"2001","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11735420","citation_count":70,"is_preprint":false},{"pmid":"19398961","id":"PMC_19398961","title":"Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.","date":"2009","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19398961","citation_count":68,"is_preprint":false},{"pmid":"19380785","id":"PMC_19380785","title":"Developmental acquisition of the Lyn-CD22-SHP-1 inhibitory pathway promotes B cell tolerance.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19380785","citation_count":67,"is_preprint":false},{"pmid":"21364532","id":"PMC_21364532","title":"Myelin suppresses axon regeneration by PIR-B/SHP-mediated inhibition of Trk activity.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/21364532","citation_count":66,"is_preprint":false},{"pmid":"9348315","id":"PMC_9348315","title":"Downregulated expression of SHP-1 in Burkitt lymphomas and germinal center B lymphocytes.","date":"1997","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9348315","citation_count":62,"is_preprint":false},{"pmid":"21291405","id":"PMC_21291405","title":"SHP-1 in cell-cycle regulation.","date":"2011","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21291405","citation_count":61,"is_preprint":false},{"pmid":"33235221","id":"PMC_33235221","title":"Intestinal FGF15/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33235221","citation_count":61,"is_preprint":false},{"pmid":"16041024","id":"PMC_16041024","title":"Heme transfer from streptococcal cell surface protein Shp to HtsA of transporter HtsABC.","date":"2005","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16041024","citation_count":60,"is_preprint":false},{"pmid":"12176909","id":"PMC_12176909","title":"SHP-1 regulates Fcgamma receptor-mediated phagocytosis and the activation of RAC.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12176909","citation_count":59,"is_preprint":false},{"pmid":"10835420","id":"PMC_10835420","title":"The protein-tyrosine phosphatase SHP-1 binds to and dephosphorylates p120 catenin.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10835420","citation_count":58,"is_preprint":false},{"pmid":"16702225","id":"PMC_16702225","title":"Sequence specificity of SHP-1 and SHP-2 Src homology 2 domains. Critical roles of residues beyond the pY+3 position.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16702225","citation_count":56,"is_preprint":false},{"pmid":"29416063","id":"PMC_29416063","title":"AhR and SHP regulate phosphatidylcholine and S-adenosylmethionine levels in the one-carbon cycle.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29416063","citation_count":53,"is_preprint":false},{"pmid":"29514104","id":"PMC_29514104","title":"Large-Scale Phosphoproteomics Reveals Shp-2 Phosphatase-Dependent Regulators of Pdgf Receptor Signaling.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29514104","citation_count":52,"is_preprint":false},{"pmid":"27486225","id":"PMC_27486225","title":"A Novel Small Molecule Activator of Nuclear Receptor SHP Inhibits HCC Cell Migration via Suppressing Ccl2.","date":"2016","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27486225","citation_count":50,"is_preprint":false},{"pmid":"29669741","id":"PMC_29669741","title":"SHP-1 regulates hematopoietic stem cell quiescence by coordinating TGF-β signaling.","date":"2018","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29669741","citation_count":49,"is_preprint":false},{"pmid":"20375098","id":"PMC_20375098","title":"Transcriptional corepressor SHP recruits SIRT1 histone deacetylase to inhibit LRH-1 transactivation.","date":"2010","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/20375098","citation_count":49,"is_preprint":false},{"pmid":"25701738","id":"PMC_25701738","title":"Interactions Between Nuclear Receptor SHP and FOXA1 Maintain Oscillatory Homocysteine Homeostasis in Mice.","date":"2015","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25701738","citation_count":48,"is_preprint":false},{"pmid":"28594363","id":"PMC_28594363","title":"Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28594363","citation_count":47,"is_preprint":false},{"pmid":"31708921","id":"PMC_31708921","title":"SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31708921","citation_count":46,"is_preprint":false},{"pmid":"19721712","id":"PMC_19721712","title":"Nuclear receptor SHP activates miR-206 expression via a cascade dual inhibitory mechanism.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19721712","citation_count":44,"is_preprint":false},{"pmid":"20516075","id":"PMC_20516075","title":"Novel polymorphisms of nuclear receptor SHP associated with functional and structural changes.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20516075","citation_count":42,"is_preprint":false},{"pmid":"10074424","id":"PMC_10074424","title":"Immune signalling: SHP-2 docks at multiple ports.","date":"1999","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/10074424","citation_count":40,"is_preprint":false},{"pmid":"22415018","id":"PMC_22415018","title":"Intravenous immunoglobulins modulate neutrophil activation and vascular injury through FcγRIII and SHP-1.","date":"2012","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/22415018","citation_count":39,"is_preprint":false},{"pmid":"19915046","id":"PMC_19915046","title":"SHP-2 expression negatively regulates NK cell function.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19915046","citation_count":37,"is_preprint":false},{"pmid":"20130595","id":"PMC_20130595","title":"Deficient SOCS3 and SHP-1 expression in psoriatic T cells.","date":"2010","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/20130595","citation_count":37,"is_preprint":false},{"pmid":"10098842","id":"PMC_10098842","title":"Tyrosine phosphorylation and association of BIT with SHP-2 induced by neurotrophins.","date":"1999","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10098842","citation_count":37,"is_preprint":false},{"pmid":"23530062","id":"PMC_23530062","title":"Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23530062","citation_count":37,"is_preprint":false},{"pmid":"20444884","id":"PMC_20444884","title":"Farnesoid X receptor activation mediates head-to-tail chromatin looping in the Nr0b2 gene encoding small heterodimer partner.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20444884","citation_count":36,"is_preprint":false},{"pmid":"15574429","id":"PMC_15574429","title":"FLT3/ITD mutation signaling includes suppression of SHP-1.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15574429","citation_count":36,"is_preprint":false},{"pmid":"34014331","id":"PMC_34014331","title":"Luteolin alleviates ulcerative colitis through SHP-1/STAT3 pathway.","date":"2021","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/34014331","citation_count":35,"is_preprint":false},{"pmid":"37263401","id":"PMC_37263401","title":"Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARα/CD36 pathway.","date":"2023","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37263401","citation_count":35,"is_preprint":false},{"pmid":"16487932","id":"PMC_16487932","title":"SHP-1 inhibits LPS-mediated TNF and iNOS production in murine macrophages.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16487932","citation_count":35,"is_preprint":false},{"pmid":"37291088","id":"PMC_37291088","title":"Targeting pathogenic macrophages by the application of SHP-1 agonists reduces inflammation and alleviates pulmonary fibrosis.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37291088","citation_count":35,"is_preprint":false},{"pmid":"24439672","id":"PMC_24439672","title":"Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.","date":"2013","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/24439672","citation_count":32,"is_preprint":false},{"pmid":"21459093","id":"PMC_21459093","title":"Nuclear receptor SHP inhibition of Dnmt1 expression via ERRγ.","date":"2011","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/21459093","citation_count":32,"is_preprint":false},{"pmid":"16223786","id":"PMC_16223786","title":"RNA interference targeting SHP-1 attenuates myocardial infarction in rats.","date":"2005","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/16223786","citation_count":32,"is_preprint":false},{"pmid":"20124506","id":"PMC_20124506","title":"Overexpression of nuclear receptor SHP in adipose tissues affects diet-induced obesity and adaptive thermogenesis.","date":"2010","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20124506","citation_count":32,"is_preprint":false},{"pmid":"31232447","id":"PMC_31232447","title":"Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.","date":"2019","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31232447","citation_count":31,"is_preprint":false},{"pmid":"37304233","id":"PMC_37304233","title":"Macrophage-derived SHP-2 inhibits the metastasis of colorectal cancer via Tie2-PI3K signals.","date":"2023","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/37304233","citation_count":30,"is_preprint":false},{"pmid":"31561841","id":"PMC_31561841","title":"Regulation of peripheral and central immunity: Understanding the role of Src homology 2 domain-containing tyrosine phosphatases, SHP-1 & SHP-2.","date":"2019","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/31561841","citation_count":30,"is_preprint":false},{"pmid":"27059688","id":"PMC_27059688","title":"Ginkgetin Blocks Constitutive STAT3 Activation and Induces Apoptosis through Induction of SHP-1 and PTEN Tyrosine Phosphatases.","date":"2016","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/27059688","citation_count":30,"is_preprint":false},{"pmid":"34752140","id":"PMC_34752140","title":"Dynamic variability in SHP-1 abundance determines natural killer cell responsiveness.","date":"2021","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/34752140","citation_count":29,"is_preprint":false},{"pmid":"27670070","id":"PMC_27670070","title":"Protein kinase D regulates positive selection of CD4+ thymocytes through phosphorylation of SHP-1.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27670070","citation_count":29,"is_preprint":false},{"pmid":"21550402","id":"PMC_21550402","title":"Ligand-independent actions of the orphan receptors/corepressors DAX-1 and SHP in metabolism, reproduction and disease.","date":"2011","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21550402","citation_count":28,"is_preprint":false},{"pmid":"19594294","id":"PMC_19594294","title":"The orphan nuclear receptor SHP is a positive regulator of osteoblastic bone formation.","date":"2010","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/19594294","citation_count":28,"is_preprint":false},{"pmid":"22438258","id":"PMC_22438258","title":"The tyrosine phosphatase SHP-1 dampens murine Th17 development.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22438258","citation_count":27,"is_preprint":false},{"pmid":"18952567","id":"PMC_18952567","title":"A critical role of SHP-1 in regulation of type 2 inflammation in the lung.","date":"2008","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18952567","citation_count":27,"is_preprint":false},{"pmid":"24379397","id":"PMC_24379397","title":"Structural insights into gene repression by the orphan nuclear receptor SHP.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24379397","citation_count":26,"is_preprint":false},{"pmid":"12769687","id":"PMC_12769687","title":"Gab1, SHP-2 and other novel regulators of Ras: targets for anticancer drug discovery?","date":"2003","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/12769687","citation_count":26,"is_preprint":false},{"pmid":"30905847","id":"PMC_30905847","title":"Inactivation of the tyrosine phosphatase SHP-2 drives vascular dysfunction in Sepsis.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/30905847","citation_count":25,"is_preprint":false},{"pmid":"24952874","id":"PMC_24952874","title":"RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24952874","citation_count":25,"is_preprint":false},{"pmid":"24343129","id":"PMC_24343129","title":"NF-κB p65 recruited SHP regulates PDCD5-mediated apoptosis in cancer cells.","date":"2014","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/24343129","citation_count":24,"is_preprint":false},{"pmid":"35034964","id":"PMC_35034964","title":"SKAP2 suppresses inflammation-mediated tumorigenesis by regulating SHP-1 and SHP-2.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35034964","citation_count":23,"is_preprint":false},{"pmid":"29518948","id":"PMC_29518948","title":"ChREBP Rather Than SHP Regulates Hepatic VLDL Secretion.","date":"2018","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/29518948","citation_count":23,"is_preprint":false},{"pmid":"27812544","id":"PMC_27812544","title":"Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity.","date":"2016","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/27812544","citation_count":23,"is_preprint":false},{"pmid":"11493654","id":"PMC_11493654","title":"SHP-2 complex formation with the SHP-2 substrate-1 during C2C12 myogenesis.","date":"2001","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/11493654","citation_count":23,"is_preprint":false},{"pmid":"28295507","id":"PMC_28295507","title":"Crocin Suppresses Constitutively Active STAT3 Through Induction of Protein Tyrosine Phosphatase SHP-1.","date":"2017","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28295507","citation_count":23,"is_preprint":false},{"pmid":"15459958","id":"PMC_15459958","title":"Mutation analysis of NR0B2 among 1545 Danish men identifies a novel c.278G>A (p.G93D) variant with reduced functional activity.","date":"2004","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/15459958","citation_count":22,"is_preprint":false},{"pmid":"32586377","id":"PMC_32586377","title":"Regulation of autoimmune arthritis by the SHP-1 tyrosine phosphatase.","date":"2020","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32586377","citation_count":22,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46936,"output_tokens":5643,"usd":0.112726},"stage2":{"model":"claude-opus-4-6","input_tokens":9105,"output_tokens":3300,"usd":0.192037},"total_usd":0.304763,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"Looking at the corpus, I need to identify papers about NR0B2 (Small Heterodimer Partner, SHP), which is an atypical nuclear receptor/corepressor. I must distinguish this from SHP-1 (PTPN6) and SHP-2 (PTPN11), which are tyrosine phosphatases that also appear frequently in this corpus under the \"SHP\" abbreviation.\n\nNR0B2 = Small Heterodimer Partner (SHP), a nuclear receptor lacking a DNA-binding domain.\nSHP-1 = PTPN6 (tyrosine phosphatase) — NOT NR0B2\nSHP-2 = PTPN11 (tyrosine phosphatase) — NOT NR0B2\n\nI'll extract only findings about NR0B2/Small Heterodimer Partner.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"Bile acid activation of FXR induces SHP (NR0B2) expression, and SHP is required for FXR-mediated repression of SREBP-1c and its lipogenic target genes, thereby lowering triglyceride levels. Genetic epistasis using SHP-null and LXRα/β-null mice demonstrated that both SHP and LXRα/β are essential for this repressive pathway.\",\n      \"method\": \"Mouse knockout models (SHP-/-, LXRα/β-/-), molecular and cellular assays, animal models of hypertriglyceridemia\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple knockout lines, replicated across molecular and animal models\",\n      \"pmids\": [\"15146238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SHP (NR0B2) is expressed in hepatic stellate cells (HSCs) and, downstream of FXR activation, directly binds JunD and inhibits AP-1 DNA binding induced by thrombin, thereby protecting against liver fibrosis. This was demonstrated using SHP-overexpressing and SHP-deficient HSC-T6 cell lines.\",\n      \"method\": \"Retroviral overexpression and siRNA knockdown of SHP in HSC-T6 cells; protein binding assays; in vivo rodent fibrosis models\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function and gain-of-function with defined molecular mechanism (JunD binding, AP-1 inhibition), supported by in vivo models\",\n      \"pmids\": [\"15521018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structure of the hLRH-1 ligand-binding domain in complex with the NR box 1 motif of human SHP (NR0B2) at 1.9 Å resolution revealed that SHP contacts the AF-2 region of hLRH-1 using selective structural motifs, establishing the structural basis for SHP-mediated corepression of LRH-1.\",\n      \"method\": \"X-ray crystallography (1.9 Å), mass spectrometry, in vivo reporter assays with LBD pocket mutations\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation by mutagenesis and in vivo assays\",\n      \"pmids\": [\"15723037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"SHP (NR0B2) interacts with and potently inhibits glucocorticoid receptor (GR) transcriptional activity via a functional second NR-box within SHP. SHP antagonizes the GR coactivator PGC-1 and represses the PEPCK promoter. Co-expression of GFP-tagged GR with SHP caused intranuclear redistribution of GR, an effect requiring SHP's inhibitory function.\",\n      \"method\": \"Mammalian and yeast two-hybrid, transient cotransfection assays, GFP imaging, inhibition-deficient SHP mutants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (protein interaction, reporter assays, live imaging, mutagenesis) in a single study\",\n      \"pmids\": [\"12324453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"SHP (NR0B2) interacts with estrogen receptor alpha (ERα) in an agonist-dependent manner via its NR-box motifs (the same domain used to interact with RXR and TR), and inhibits estradiol-dependent ERα transcriptional activation ~5-fold. SHP also interacts with ERβ in a ligand-independent manner.\",\n      \"method\": \"Mammalian and yeast two-hybrid, GST pull-down, deletion mutant mapping, transient cotransfection reporter assays\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding assays plus functional reporter assays, multiple ER isoforms tested\",\n      \"pmids\": [\"9773978\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"SHP (NR0B2) inhibits androgen receptor (AR) transcriptional activity by up to 97% through ligand-dependent interaction with the AR ligand-binding domain via LXXI/LL motifs, and also interacts with the AR N-terminal domain, enabling inhibition of both LBD- and NTD-dependent transactivation. SHP competes with AR coactivators FHL2 and TIF2.\",\n      \"method\": \"Two-hybrid assays, deletion mutant analysis, transient cotransfection reporter assays, coactivator competition assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple interaction assays plus functional reporter data with domain mapping and coactivator competition\",\n      \"pmids\": [\"11735420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SHP (NR0B2) recruits SIRT1 histone deacetylase to inhibit LRH-1 transactivation in an NR-specific manner. SHP and SIRT1 co-immunoprecipitate and co-localize in vivo. SIRT1 deacetylates histones H3 and H4 at LRH-1 target gene promoters (CYP7A1, SHP itself), and inhibition of SIRT1 reverses SHP-mediated repression of bile acid synthesis.\",\n      \"method\": \"Co-IP, co-localization, ChIP assays, dominant-negative SIRT1, siRNA knockdown, luciferase reporter assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, ChIP, and functional assays with multiple loss-of-function approaches\",\n      \"pmids\": [\"20375098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Crystal structure of SHP (NR0B2) in complex with EID1 revealed that EID1 binds an unexpected N-terminal site on SHP (mimicking helix H1 of the NR LBD), distinct from the classical C-terminal H12 cofactor-binding site. Mutations at this interface diminish SHP-EID1 interactions and impair SHP repressor activity.\",\n      \"method\": \"X-ray crystallography, mutagenesis, protein interaction assays, functional reporter assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis validation and functional assays\",\n      \"pmids\": [\"24379397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FGF15/19 activates SHP (NR0B2) via phosphorylation, and phosphorylated SHP recruits DNMT3A to lipogenic gene promoters, leading to epigenetic repression via DNA methylation. This FGF15/19-SHP-DNMT3A axis physiologically represses hepatic lipogenesis in the late fed state.\",\n      \"method\": \"Comparative genomics, adenoviral overexpression, SHP knockout mice, ChIP, bisulfite sequencing, phosphorylation assays, DNMT3A-knockout validation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods including phosphorylation, ChIP, DNA methylation, and in vivo knockout models\",\n      \"pmids\": [\"33235221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FXR activates SHP (NR0B2) transcription through two FXR response elements (FXRREs): one in the proximal promoter and one in a novel downstream 3'-enhancer of the Nr0b2 gene. These two FXRREs interact to form a head-to-tail chromatin loop as detected by chromatin conformation capture assay, enhancing transcription efficiency.\",\n      \"method\": \"ChIP-seq, ChIP-qPCR, chromatin conformation capture (3C), luciferase reporter assays, site-directed mutagenesis\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — 3C chromatin looping plus ChIP-seq and mutagenesis provide strong mechanistic evidence\",\n      \"pmids\": [\"20444884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Combined deletion of both Fxr and Shp (NR0B2) in mice causes juvenile-onset cholestasis more severe than either single knockout, demonstrating that FXR and SHP have partially non-overlapping functions. The double knockout induced Cyp17a1, elevated 17-hydroxyprogesterone (17-OHP), and 17-OHP treatment alone was sufficient to reproduce liver injury.\",\n      \"method\": \"Double knockout mouse model, gene expression analysis, serum metabolite measurement, pharmacological 17-OHP treatment\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with double KO and pharmacological rescue, replicated across multiple endpoints\",\n      \"pmids\": [\"21123943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"SHP (NR0B2) inhibits CYP7A1 transcription by associating with LRH-1 (liver receptor homolog-1), an obligate transcriptional activator of CYP7A1, thereby repressing bile acid synthesis downstream of FXR-induced SHP expression.\",\n      \"method\": \"Molecular and cellular studies reviewed; interaction assays and transcriptional reporter assays cited across multiple studies\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review summarizing interaction data; primary experiments cited from other labs\",\n      \"pmids\": [\"11907135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SHP (NR0B2) activates miR-206 expression through a cascade dual inhibitory mechanism: SHP inhibits ERRγ, which reduces YY1 expression, which in turn de-represses AP-1 activity on the miR-206 promoter. ChIP confirmed ERRγ binding to the YY1 promoter and AP1/YY1 binding to the miR-206 promoter.\",\n      \"method\": \"Microarray profiling, RACE, ChIP assays, siRNA knockdown, promoter reporter assays, forced expression\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP, siRNA, reporter assays) establishing a cascade mechanism\",\n      \"pmids\": [\"19721712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SHP (NR0B2) polymorphisms R38H and K170N impair nuclear translocation. K170N increases susceptibility to ubiquitination-mediated degradation and blocks SHP acetylation, leading to loss of repressive activity on ERRγ and HNF4α (but not LRH-1). K170N also impairs recruitment of SHP, HNF4α, HDAC1, and HDAC3 to the apoCIII promoter.\",\n      \"method\": \"SNP identification, nuclear localization assays, ubiquitination assays, acetylation assays, ChIP, reporter assays, molecular dynamics simulation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple biochemical assays plus structural modeling, mutagenesis, and ChIP\",\n      \"pmids\": [\"20516075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SHP (NR0B2) represses Dnmt1 expression by inhibiting ERRγ transactivation at ERRγ response elements in the Dnmt1 promoter, reducing ERRγ recruitment and shifting local chromatin to an inactive conformation.\",\n      \"method\": \"Luciferase reporter assays, ChIP assays, ERRγ and SHP overexpression/knockdown\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and reporter assays from a single lab\",\n      \"pmids\": [\"21459093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SHP (NR0B2) overexpression in adipose tissue increases body weight and adiposity in young transgenic mice, impairs adaptive thermogenesis on high-fat diet, and decreases energy expenditure and physical activity, establishing a direct role for adipose SHP in metabolic regulation.\",\n      \"method\": \"Fat-specific SHP transgenic mice, metabolic rate measurement, cold-exposure studies, high-fat diet feeding, brown fat ultrastructural analysis\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific transgenic model with defined metabolic phenotypes, single lab\",\n      \"pmids\": [\"20124506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SHP (NR0B2) physically interacts with Runx2 on the osteocalcin gene promoter and increases Runx2 transactivity by competing with HDAC4, which normally inhibits Runx2 DNA binding. SHP-/- mice show decreased bone mass and reduced osteoblast numbers.\",\n      \"method\": \"Co-IP, ChIP, reporter assays, SHP-/- mice, adenoviral overexpression/knockdown, ectopic bone formation assay\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (Co-IP, ChIP, KO mice, functional assays) with defined molecular mechanism\",\n      \"pmids\": [\"19594294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SHP (NR0B2) inhibits transcriptional activation of Bhmt and cystathionine γ-lyase by FOXA1, thereby controlling oscillatory homocysteine homeostasis. SHP-null mice show altered timing of expression of homocysteine metabolism genes and resistance to ethanol/homocysteine-induced hyperhomocysteinemia and glucose intolerance.\",\n      \"method\": \"SHP-null and BHMT-null mouse models, RNA-seq, ChIP assays, metabolomics\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse model combined with ChIP and metabolomics establishing FOXA1-SHP interaction and gene targets\",\n      \"pmids\": [\"25701738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"AhR and SHP (NR0B2) regulate phosphatidylcholine and S-adenosylmethionine levels by controlling Pemt and Gnmt expression. Insulin/PKB signaling translocates AhR to the nucleus to induce these genes in the early fed state, while FGF15 signaling-activated SHP blocks this induction in the late fed state.\",\n      \"method\": \"SHP-null and FGF15-null mice, adenoviral expression, ChIP assays, metabolomics\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO models combined with ChIP and metabolomics establishing AhR-SHP epistasis\",\n      \"pmids\": [\"29416063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A small molecule (DSHN) activates SHP (NR0B2) by transcriptionally upregulating Shp mRNA and stabilizing SHP protein by preventing ubiquitination and degradation. Activated SHP represses Ccl2 expression by inhibiting p65-mediated CCL2 promoter activity, thereby inhibiting HCC cell migration.\",\n      \"method\": \"Small molecule microarray binding assay, RNA-seq, luciferase reporter assays, SHP overexpression/knockdown, ubiquitination assay, Shp-/- mice\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods with in vivo validation in Shp-/- mice\",\n      \"pmids\": [\"27486225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SHP (NR0B2) is recruited by NF-κB p65 and forms a SHP/NF-κB p65 complex that binds the PDCD5 gene promoter, activating PDCD5 expression and triggering apoptosis via increased Bax and cytochrome C release in breast cancer cells.\",\n      \"method\": \"ChIP-on-chip, ChIP assay, luciferase reporter assay, knockdown/overexpression of SHP and PDCD5, apoptosis assays\",\n      \"journal\": \"Apoptosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and functional assays, single lab\",\n      \"pmids\": [\"24343129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"A novel missense variant G93D in NR0B2 (SHP) shows reduced in vitro inhibition of HNF-4α transactivation of the HNF-1α promoter in MIN6-m9 and HepG2 cells, establishing that Gly-93 is functionally important for SHP's corepressor activity.\",\n      \"method\": \"SSCP/heteroduplex mutation screening, transfection reporter assays in MIN6-m9 and HepG2 cells\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro functional assay with human variant, single lab\",\n      \"pmids\": [\"15459958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ChREBP, rather than SHP (NR0B2), is the primary regulator of hepatic MTTP expression and VLDL secretion under normal conditions. Shp-/- mice show similar Mttp mRNA, protein, and VLDL secretion to wild-type, while Chrebp-/-Shp-/- and Chrebp-/- mice show markedly lower levels, demonstrating genetic epistasis.\",\n      \"method\": \"Shp-/- and Chrebp-/- single and double knockout mice, adenoviral overexpression in primary hepatocytes, VLDL secretion assays, promoter reporter assays\",\n      \"journal\": \"Nutrients\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with double KO, single lab\",\n      \"pmids\": [\"29518948\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NR0B2/SHP is an atypical nuclear receptor lacking a DNA-binding domain that acts as a broadly inducible transcriptional corepressor: it is transcriptionally induced by FXR (via chromatin looping between a proximal FXRRE and a distal 3' enhancer in the Nr0b2 gene), and FGF15/19-mediated phosphorylation of SHP enables it to recruit epigenetic repressors including SIRT1 histone deacetylase and DNMT3A to lipogenic and other metabolic gene promoters; SHP directly interacts with numerous nuclear receptors (LRH-1, GR, ERα, AR, ERRγ, HNF-4α, Runx2) and transcription factors (JunD/AP-1, FOXA1, p65) via its NR-box motifs, inhibiting their transcriptional activity through competition with coactivators and recruitment of corepressor complexes, and its stability is regulated by ubiquitination and acetylation at Lys-170.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"NR0B2 (SHP) is an atypical orphan nuclear receptor that lacks a DNA-binding domain and functions as a versatile transcriptional corepressor in hepatic bile acid, lipid, and one-carbon metabolism, as well as in bone remodeling and inflammatory signaling. SHP is transcriptionally induced by FXR through chromatin looping between proximal and distal FXR response elements, and is post-translationally activated by FGF15/19-mediated phosphorylation, which enables recruitment of epigenetic silencing machinery including SIRT1 histone deacetylase and DNMT3A DNA methyltransferase to target gene promoters [PMID:20444884, PMID:20375098, PMID:33235221]. SHP binds a broad array of nuclear receptors (LRH-1, GR, ERα, AR, ERRγ, HNF-4α) and transcription factors (JunD/AP-1, FOXA1, p65) through its NR-box motifs, competing with coactivators at the AF-2 surface to repress transcription of genes controlling bile acid synthesis (CYP7A1), lipogenesis (SREBP-1c targets), gluconeogenesis (PEPCK), and homocysteine metabolism (Bhmt, Cth) [PMID:15723037, PMID:15146238, PMID:12324453, PMID:25701738]. SHP protein stability is regulated by ubiquitination and acetylation at Lys-170, and naturally occurring variants such as K170N and R38H impair nuclear translocation and corepressor function [PMID:20516075].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Establishing that SHP functions as a ligand-modulated inhibitor of steroid receptors answered the question of how an orphan NR lacking a DBD exerts transcriptional effects — SHP directly binds ERα via NR-box motifs and represses estrogen-dependent transactivation.\",\n      \"evidence\": \"Mammalian/yeast two-hybrid, GST pull-down, and reporter assays mapping NR-box-dependent SHP–ERα interaction\",\n      \"pmids\": [\"9773978\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous ligand for SHP's LBD pocket not identified\", \"In vivo relevance of SHP–ERα interaction not tested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating that SHP inhibits AR through both LBD- and NTD-dependent interactions and competes with coactivators FHL2/TIF2 broadened the corepressor model beyond steroid receptor LBD contacts.\",\n      \"evidence\": \"Two-hybrid, deletion mapping, reporter assays, and coactivator competition assays\",\n      \"pmids\": [\"11735420\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological context of SHP–AR antagonism undefined\", \"No in vivo data\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showing that SHP antagonizes GR by competing with PGC-1 and causing intranuclear redistribution of GR connected SHP to gluconeogenic gene regulation (PEPCK).\",\n      \"evidence\": \"Mammalian/yeast two-hybrid, GFP live imaging, reporter assays with inhibition-deficient SHP mutants\",\n      \"pmids\": [\"12324453\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo metabolic consequence of SHP–GR antagonism not demonstrated\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Genetic epistasis with SHP-null and LXRα/β-null mice established that FXR-induced SHP is required for repression of SREBP-1c and triglyceride lowering, positioning SHP as an essential node in the bile acid–lipogenesis regulatory axis.\",\n      \"evidence\": \"SHP−/− and LXRα/β−/− knockout mice, molecular assays, hypertriglyceridemia models\",\n      \"pmids\": [\"15146238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which SHP inhibits LXRα-mediated SREBP-1c transcription not fully resolved at the chromatin level\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of SHP–JunD binding and inhibition of AP-1 activity in hepatic stellate cells extended SHP's repressor role beyond nuclear receptors to non-NR transcription factors and linked it to protection against liver fibrosis.\",\n      \"evidence\": \"Retroviral overexpression and siRNA knockdown in HSC-T6 cells, protein binding assays, rodent fibrosis models\",\n      \"pmids\": [\"15521018\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct structural basis of SHP–JunD interaction unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The 1.9 Å crystal structure of SHP NR-box 1 bound to the LRH-1 AF-2 surface provided the first atomic-level explanation for how SHP mimics coactivator binding to repress target NRs.\",\n      \"evidence\": \"X-ray crystallography, mass spectrometry, mutagenesis, in vivo reporter assays\",\n      \"pmids\": [\"15723037\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of full-length SHP or its complex with other NR partners not determined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery that SHP activates miR-206 through a cascade (SHP→ERRγ→YY1→AP-1) revealed SHP can upregulate gene expression indirectly through serial repression.\",\n      \"evidence\": \"Microarray, ChIP, siRNA knockdown, reporter assays\",\n      \"pmids\": [\"19721712\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of miR-206 regulation by SHP not validated in vivo\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Multiple 2010 studies resolved how SHP's own transcription is controlled (FXR-mediated chromatin looping), how SHP represses chromatin (SIRT1 recruitment to deacetylate H3/H4), and how post-translational modifications (ubiquitination, acetylation at K170) regulate SHP stability and partner selectivity.\",\n      \"evidence\": \"ChIP-seq, 3C chromatin conformation capture, Co-IP/co-localization, ubiquitination/acetylation assays, SHP−/− mice, molecular dynamics, SNP functional analysis\",\n      \"pmids\": [\"20444884\", \"20375098\", \"20516075\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for SHP phosphorylation not yet assigned in this context\", \"Whether K170 acetylation is enzymatically reversible in vivo unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"SHP−/− mice exhibit decreased bone mass and reduced osteoblast numbers; SHP promotes Runx2 transactivation by displacing HDAC4 from the osteocalcin promoter, establishing a coactivator-like role for SHP in bone.\",\n      \"evidence\": \"Co-IP, ChIP, reporter assays, SHP−/− mice, ectopic bone formation assay\",\n      \"pmids\": [\"19594294\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals activating SHP in osteoblasts unidentified\", \"Whether SHP–Runx2 interaction is NR-box-dependent not shown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Double knockout of Fxr and Shp caused juvenile cholestasis more severe than either single KO, with ectopic Cyp17a1 induction and elevated 17-OHP, revealing non-overlapping protective functions of FXR and SHP.\",\n      \"evidence\": \"Fxr−/−;Shp−/− double KO mice, gene expression, serum metabolites, pharmacological 17-OHP challenge\",\n      \"pmids\": [\"21123943\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which SHP represses Cyp17a1 not determined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"The SHP–EID1 crystal structure revealed a non-canonical cofactor-binding site at the N-terminal helix H1 of SHP's LBD, distinct from the classical AF-2 groove, expanding the structural repertoire of SHP-mediated repression.\",\n      \"evidence\": \"X-ray crystallography, mutagenesis, protein interaction and reporter assays\",\n      \"pmids\": [\"24379397\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the H1 site operates simultaneously with the AF-2 site in a ternary complex is unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"SHP was shown to govern oscillatory homocysteine homeostasis by inhibiting FOXA1 transactivation of Bhmt and Cth, connecting SHP to one-carbon metabolism and linking its loss to ethanol-induced hyperhomocysteinemia.\",\n      \"evidence\": \"SHP-null and BHMT-null mice, RNA-seq, ChIP, metabolomics\",\n      \"pmids\": [\"25701738\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether circadian regulation of SHP drives the oscillatory pattern not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"SHP was placed into a temporal feeding-cycle circuit: insulin/PKB-driven AhR activates Pemt/Gnmt in the early fed state, while FGF15-activated SHP blocks this induction in the late fed state, controlling phosphatidylcholine and SAM levels.\",\n      \"evidence\": \"SHP-null and FGF15-null mice, ChIP, metabolomics\",\n      \"pmids\": [\"29416063\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct SHP–AhR physical interaction not demonstrated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The FGF15/19–SHP–DNMT3A epigenetic axis was defined: FGF15/19-mediated phosphorylation of SHP enables DNMT3A recruitment to lipogenic promoters, causing DNA methylation-dependent repression in the late fed state.\",\n      \"evidence\": \"Comparative genomics, SHP-KO mice, ChIP, bisulfite sequencing, phosphorylation assays, DNMT3A-KO validation\",\n      \"pmids\": [\"33235221\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific phosphorylation site(s) on SHP mediating DNMT3A recruitment not mapped\", \"Reversibility and dynamics of DNA methylation marks unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of any endogenous SHP ligand, the full-length SHP structure, how SHP switches between corepressor and apparent coactivator roles (e.g., Runx2), and the tissue-specific regulation of SHP post-translational modifications.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No endogenous ligand identified\", \"No full-length SHP structure\", \"Mechanism governing context-dependent coactivator vs corepressor activity unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 3, 4, 5, 6, 12, 14, 17]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 6, 8, 16, 19, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 6, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 6, 8, 9, 12, 14, 17, 19, 20]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 8, 15, 17, 18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 18]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [6, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"NR5A2\",\n      \"NR1H4\",\n      \"NR3C1\",\n      \"ESR1\",\n      \"AR\",\n      \"ESRRG\",\n      \"SIRT1\",\n      \"DNMT3A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}